About: HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.06 (-1.85%)
HCWB NASDAQ HCW Biologics Inc
HCW Biologics Inc share price
HCWB price activity
Last Price
$1.060
Change (24hr)
-0.02 USD (1.85%)
Volume
28.43K
Volume (4w avg)
-
Previous Close
$1.08
Last Trade
05 Nov, 2:12 pm GMT+0
Delayed
05 Nov, 2:12 pm GMT+0
HCWB price performance
Delayed
05 Nov, 2:12 pm GMT+0
HCWB details
HCWB Market Signals